(Total Views: 91)
Posted On: 12/07/2023 8:25:45 AM
Post# of 9

$SNYNF News Article - Press Release: Sarclisa (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant https://marketwirenews.com/news-releases/pres...90596.html


My Twitter: WhyteStocks